NasdaqCM - Nasdaq Real Time Price USD

RedHill Biopharma Ltd. (RDHL)

0.4562

-0.0038

(-0.83%)

As of 12:48 PM EDT. Market Open.

RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035

RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the issue of a new Chinese patent Notice of Allowance covering opaganib[1] as a therapyg for inhibition of single-stranded RNA virus replication (notably Ebola Disease Virus) from the Chinese National Intellectual Property Administration (CNIPA), valid through 2035 (Chinese Patent Application No.: 202110229970.9 issued April 29, 2024).

PR Newswire 8 days ago

RDHL
-0.83%
RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the first patient has been enrolled in the Austere environments Consortium for Enhanced Sepsis Outcomes' (ACESO) U.S. government-supported PROTECT multinational platform trial for early COVID-19 outpatient treatment. RHB-107 (upamostat) is the first drug being tested in this platform study. Funded through non-dilutive external sources, including the U.S. Department of D

PR Newswire 20 days ago

RDHL
-0.83%
HPHA.F
RedHill Biopharma Full Year 2023 Earnings: EPS: US$4.00 (vs US$46.29 loss in FY 2022)

RedHill Biopharma ( NASDAQ:RDHL ) Full Year 2023 Results Key Financial Results Net income: US$23.9m (up from US$71.7m...

Simply Wall St. last month

RDHL
-0.83%
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights

RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its full year 2023 financial results and operational highlights and associated filing of its annual report on Form 20-F for the year ended December 31, 2023.

PR Newswire last month

RDHL
-0.83%
RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into definitive agreements with private investors for the purchase and sale, at a premium, of 2,144,487 of the Company's American Depositary Shares ("ADSs"), each ADS representing four hundred (400) ordinary shares, par value NIS 0.01 per share, of the Company, and warrants to purchase up to an aggregate of 2,144,487ADSs, at a purchase price of $0.58289 p

PR Newswire last month

RDHL
-0.83%
RedHill Announces New USPTO Patent Covering Talicia® Through 2034

RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the issue of a new U.S. patent covering Talicia1 as an all-in-one fixed-dose combination of amoxicillin, omeprazole and rifabutin and its use for the treatment of helicobacter pylori (H. pylori) infection (Patent No. 11,931,463 to be issued March 19, 20244). Talicia is the leading branded first-line therapy prescribed by U.S. gastroenterologists for H. pylori infection, whic

PR Newswire 2 months ago

RDHL
-0.83%
RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, together with its partner Apogee Biotechnology Corporation, today announced that opaganib[2] has been selected by the U.S. government's Chemical Medical Countermeasures (Chem MCM) Program and Chemical Countermeasures Research Program (CCRP) for evaluation as a potential medical countermeasure (MCM) against inhalation Sulfur Mustard exposure. The overall evaluation will also include assessme

PR Newswire 2 months ago

RDHL
-0.83%
RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced a new publication of data from multiple experiments in the International Journal of Molecular Sciences1. The published data shows that opaganib2 protects against radiation-induced lung inflammation and fibrosis in an in vivo mouse model of lung damage following exposure to ionizing radiation, demonstrating its potential use as a medical countermeasure against nuclear irradia

PR Newswire 2 months ago

RDHL
-0.83%
RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering

RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 10,000,000 of the Company's American Depositary Shares ("ADSs"), each ADS representing four hundred (400) ordinary shares, at a purchase price of $0.80 per ADS. In addition, in a concurrent private placement, the Company issued unregistered warrants to purchase up to 10,000,00

PR Newswire 3 months ago

RDHL
-0.83%
RedHill Biopharma Announces $8 Million Registered Direct Offering

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of 10,000,000 of the Company's American Depositary Shares ("ADSs"), each ADS representing four hundred (400) ordinary shares, at a purchase price of $0.80 per ADS, in a registered direct offering. In addition, in a concurrent private placement, the Company will issue unregis

PR Newswire 3 months ago

RDHL
-0.83%
RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) issued a new patent, U.S. Patent No. 11,878,011, covering Talicia as a method for eradicating Helicobacter pylori (H. pylori) regardless of patient Body Mass Index (BMI). This new patent is expected to provide protection for Talicia until May 2042.

PR Newswire 3 months ago

RDHL
-0.83%
RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that its two novel, oral host-directed investigational drugs, opaganib[1] and RHB-107 (upamostat)[2], demonstrated robust synergistic effect when combined individually with remdesivir (Veklury®)[3], significantly improving viral inhibition while maintaining cell viability, in a new U.S. Army-funded and conducted Ebola virus in vitro study.

PR Newswire 4 months ago

RDHL
-0.83%
HPHA.F

GILD
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it received confirmation from The Nasdaq Stock Market LLC ("Nasdaq") that it had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1) for continued Nasdaq listing, and is now compliant with applicable listing standards for continued Nasdaq listing. To regain compliance with Nasdaq Listing Rule 5550(a)(2), the Company was requir

PR Newswire 4 months ago

RDHL
-0.83%
RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced new non-dilutive external funding, additional to the previously announced U.S. Government funding, which now covers the entirety of the RHB-107 (upamostat) arm of the ACESO PROTECT adaptive platform trial for early COVID-19 outpatient treatment. This additional funding amounts to approximately $4.8M directed towards evaluation of RHB-107 in the PROTECT study.

PR Newswire 5 months ago

RDHL
-0.83%
RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034

RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced that the U.S. FDA (U.S. Food and Drug Administration) has granted five years' market exclusivity for Talicia3 under the Generating Antibiotic Incentives Now (GAIN) Act Qualified Infectious Disease Product (QIDP) designation, as recommended by the FDA Exclusivity Board. This grant is on top of three years' exclusivity granted for the approval of Talicia under section 505(b)(2). Tal

PR Newswire 5 months ago

RDHL
-0.83%
RedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital Market

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has received approval from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") to transfer the listing of the American Depositary Shares ("ADSs") to the Nasdaq Capital Market. The ADSs will be transferred to the Nasdaq Capital Market at the opening of business on November 15, 2023.

PR Newswire 5 months ago

RDHL
-0.83%
RedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that novel, twice daily, oral opaganib[1], delivered a statistically significant increase in survival time when given at 150 mg/kg twice a day (BID) in a United States Army Medical Research Institute of Infectious Diseases (USAMRIID) in vivo Ebola virus study, making it the first host-directed molecule to show activity in Ebola virus disease.

PR Newswire 7 months ago

RDHL
-0.83%
RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that on September 19, 2023, it received a letter from the Listings Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, for the thirty consecutive business days from August 7, 2023, to September 18, 2023, the bid price for the Company's American Depositary Shares ("ADSs") had closed below the minimum $1.00 per share requirement for continued l

PR Newswire 7 months ago

RDHL
-0.83%
RedHill Announces FDA sNDA Approval for Talicia®

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced the U.S. Food and Drug Administration's (FDA) approval of its supplemental new drug application (sNDA) for Talicia[3], allowing a change to a more flexible three times daily (TID), taken at least 4 hours apart with food, dosing regimen for H. pylori eradication. This differs from the previously approved dosing regimen (Q8H), which required dosing every eight hours with food, by en

PR Newswire 7 months ago

RDHL
-0.83%
RedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA®)

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) had issued a Notice of Allowance for a new opaganib[1] patent covering sphingosine kinase 2 inhibition treatment for Ebola virus disease, supporting opaganib pro tection until October 2035. The Company also announced that the European Patent Office has granted RHB-102 (BEKINDA)[2] a new patent, covering ondansetron extended-r

PR Newswire 8 months ago

RDHL
-0.83%

Performance Overview

Return	RDHL	MSCI WORLD
YTD	-68.75%	+8.01%
1-Year	-80.17%	+21.84%
3-Year	-99.81%	+18.34%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

RedHill Biopharma Ltd. (RDHL)

RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035

RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study

RedHill Biopharma Full Year 2023 Earnings: EPS: US$4.00 (vs US$46.29 loss in FY 2022)

RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights

RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price

RedHill Announces New USPTO Patent Covering Talicia® Through 2034

RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs

RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication

RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering

RedHill Biopharma Announces $8 Million Registered Direct Offering

RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042

RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study

RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034

RedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital Market

RedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study

RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

RedHill Announces FDA sNDA Approval for Talicia®

RedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA®)

Performance Overview